The Danish pharmaceutical company Novo Nordisk is investing 800 million dollars to upgrade and expand its production facilities in Kalundborg.
It informs the company in a press release.
Kalundborg factory currently produces a range of products in the field of diabetes treatment.
the Plan is that the factory must be upgraded and expanded so that it also can produce these products in the future as well as the next generation of diabetesprodukter.
See also: Novo-boss scores a wage increase of 72 percent at three years
the Upgrade and the extensions are expected to be completed in 2022.
Novo Nordisk, indicating in the message is not, whether the investments are going to lead to the hiring of additional employees.
There are currently more than 3000 employees at the Kalundborg factory.
- This investment in our production facilities demonstrates our ambition to continue to strengthen our presence in Denmark and Kalundborg.
- today we produce about half of the world's insulin in Kalundborg, denmark, where we have been present for 50 years.
- Since the start of the new millennium, we have only invested more than 16 billion dollars in these facilities, which is a cornerstone in our global production network, says Michael Hallgren, who is the director of the Novo Nordisk's production in Kalundborg, denmark, in the press release.
the News of the investment in the Kalundborg factory comes after Novo Nordisk Thursday published financial statements for 2019.
It showed a revenue growth of nine percent to 122 billion dollars, among other things, thanks to a growth in the large and important market in the UNITED states.
See also: Microsoft will in 2030 remove more CO2 than is emitted
